Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by HighSkies2019on Jul 21, 2021 7:07am
124 Views
Post# 33580223

Moon Shot !!!

Moon Shot !!!Though I was not into the rs idea for same reason as most investors....I looked at all current facts with such low stk price and extremely high qty of outstanding shares it is not a pretty pic to attract interest of big buyers ..even with good results from testing too many shares out there means more buying and selling tactics for shorts or day traders and more chance for their purchase to fail dollar wise ...after split with less shares and price calculated up...they could then offer a decent price ...and with less shares on the market would make them more in demand ... especially if a big name attached to us .. price could fly quickly ....who knows maybe rs Friday after close followed up on Monday with news of finacial support of sort...no one knows for sure ...its been pretty tight lip lately...but finally we are on the move....hoping for a moon shot much higher then Bezos who when further then Branson glta
<< Previous
Bullboard Posts
Next >>